A at a glance
Agilent Technologies (A, SEC CIK 1090872) filed its latest 10-K annual report on December 22, 2025, a 10-Q quarterly report on September 1, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended October 31, 2025 (FY2025), Agilent Technologies (A) reported revenue of $6.9 billion (up 6.7% from FY2024) and net income of $1.3 billion. Diluted EPS was $4.57.
- As of June 30, 2026, 42 institutional investment managers tracked by SignalX reported holding Agilent Technologies (A) shares worth $15.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Dolsten Mikael on September 4, 2026 of 634 shares at $151.38 per share.
- In the last 90 days, A insiders reported 0 open-market purchases ($0) and 1 open-market sale ($96K) on Form 4, a net sale of $96K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.9B
- +6.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$96K
- 13F holders
- 42 funds
- $15.4B · −1 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Oct 31, 2025
Risk Factors
- Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025
- Geopolitical risk from U.S. tariff changes in H2 2025 increasing cost of revenue; mitigation expected in fiscal 2026 through supply chain and pricing actions
- Operational risk in inventory valuation: potential write-downs if actual market conditions worsen beyond management's estimates on excess and obsolete inventory
- Competitive risk from capital spending declines in pharmaceutical market affecting Life Sciences and Diagnostics segment revenue growth, down 11% in 2024 vs 2023
- Financial risk from goodwill and intangible asset impairment assessment, relying on significant estimates including revenue growth and discount rates, with no impairment recognized in 2025
Business Overview
- Core business model: Provider of scientific instruments and analytical solutions for laboratories and research
- No new products, services, or business segments introduced or emphasized in this year's filing
- Continued focus on equity compensation plans, including 2018 Stock Plan with 38.8 million shares available for future issuance
- Notable metric: 2,954,318 securities outstanding under equity compensation plans with weighted-average exercise price $134
- Most unusual detail: Annual increase mechanism in Employee Stock Purchase Plan allows up to 1% of outstanding shares for future issuance
Management Discussion & Analysis
- Revenue and profitability figures not disclosed in provided MD&A text
- No cash flow, buybacks, dividends, or capex details mentioned
- Forward-looking statements highlight growth opportunities, investments, market demand, and macroeconomic risks without specific guidance or figures
AI summary of the A 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 31, 2026
Management Discussion & Analysis
- Revenue $1,878M, up 8% YoY from $1,738M
- Operating margin 23.6% vs 20.7% YoY; gross margin 55.5% vs 51.1%
- Best segment Life Sciences and Diagnostics Markets: $746M, up 11% YoY
- Operating cash flow $1,064M vs $1,014M; $78M share repurchases and $72M dividends
- Outlook: normalized customer capital budgets; tariff and Middle East risks remain dynamic
Risk Factors
- No explicit newly added risk identified; filing continues previously disclosed business, regulatory, and financial risks
- International exposure: foreign-exchange movements favorably affected revenue growth by 2 percentage points in nine months ended July 31, 2026
- Privacy compliance: GDPR violations can trigger fines of up to 4% of total company revenue
- Trade and geopolitical disruption: tariffs, sanctions, and export controls may restrict shipments and critical-component sourcing
- Demand volatility: customer orders remain difficult to forecast and may be delayed or cancelled during market declines
AI summary of the A 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chairperson Boon Hwee Koh retiring September 4, 2026 after 23 years, with no operational or policy disagreements
- Glenn Boehnlein appointed Class III director effective September 4, 2026, standing for re-election at the 2027 annual meeting
Item 7.01: Regulation FD Disclosure
- Board transition: Mr. Koh retiring; Mr. Boehnlein appointed as Agilent director
- Press release dated September 8, 2026 contains additional transition details in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Board chair Koh Boon Hwee retired September 4 after more than 20 years, ending long-standing governance continuity
- Dow R. Wilson became chair, supporting leadership continuity with company knowledge and prior Audit and Finance Committee experience
Item 2.02: Results of Operations and Financial Condition
- Agilent’s 2.02 filing directs investors to Exhibit 99.1 for fiscal 2026 results and detailed financial metrics
- Management emphasizes non-GAAP performance measures for ongoing operations and competitor comparisons
Item 1.01: Entry into a Material Definitive Agreement
- $600M senior unsecured notes issued at 4.900% interest, due January 15, 2032
- Annual interest expense approximately $29.4M before issuance discounts, payable semi-annually from January 15, 2027
AI summaries of A 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for A
Don't miss the next A filing
- Alerts as it files. A push when A files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut A, by share count.
- Ask anything. An AI agent that reads every A filing and answers with sources.
A alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Boehnlein Glenn S | A | Sep 8, 2026 | 817 | $146.85 |
| Dolsten Mikael | Sell | Sep 4, 2026 | 634 | $151.38 |
| KIRKWOOD JONAH PREVOST | F | Jun 26, 2026 | 30 | $136.01 |
| MCDONNELL PADRAIG | F | Jun 3, 2026 | 418 | $137.40 |
| MAY SIMON | F | May 8, 2026 | 368 | $115.62 |
| Henson Meghan | F | Mar 31, 2026 | 153 | $113.98 |
| KOH BOON HWEE | F | Mar 19, 2026 | 648 | $111.75 |
| KOH BOON HWEE | A | Mar 19, 2026 | 2,158 | $111.75 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.5B | $6.9B |
| Operating Income | - | $1.5B | $1.5B |
| Net Income | $1.2B | $1.3B | $1.3B |
| Op. Margin | - | 22.9% | 21.3% |
| Net Margin | - | 19.8% | 18.8% |
| Balance Sheet | |||
| Total Assets | $10.8B | $11.8B | $12.7B |
| Equity | - | $5.9B | $6.7B |
| ROE | - | 21.9% | 19.3% |
| Per Share | |||
| EPS | $4.19 | $4.43 | $4.57 |
| Cash Flow | |||
| Operating CF | - | $1.8B | $1.6B |
| CapEx | $298.0M | $378.0M | $407.0M |
Source: XBRL data in Agilent Technologies (A)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate A share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 42 | $15.43B |
| Q1 2026 | 43 | $12.40B |
| Q4 2025 | 41 | $14.29B |
| Q3 2025 | 42 | $13.65B |
| Q2 2025 | 40 | $12.31B |
| Q1 2025 | 38 | $8.96B |
| Q4 2024 | 33 | $8.80B |
| Q3 2024 | 28 | $4.19B |
- FMR LLC (Fidelity)+4.16M (+454%)
- BNY Mellon+2.44M (+87%)
- Goldman Sachs Group+1.13M (+32%)
- AQR Capital Management+609.1K (+20%)
- T. Rowe Price Group+601.7K (+146%)
- Citadel Advisors LLC−700.2K (-39%)
- Two Sigma Investments−653.8K (-97%)
- Millennium Management−594.6K (-87%)
- BlackRock−303.7K (-1%)
- Ameriprise Financial−252.1K (-21%)
- Renaissance Technologies LLC−300.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 307 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
A filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 10-Q | Sep 1, 2026 | Jul 31, 2026 | Analysis | |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 10-Q | Jun 1, 2026 | Apr 30, 2026 | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| SC 13G | Apr 28, 2026 | - | - | |
| 8-K | Apr 6, 2026 | - | Analysis | - |
| 8-K | Apr 3, 2026 | - | Analysis | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
A SEC filings: frequently asked questions
Are A insiders buying or selling?
In the last 90 days, Agilent Technologies (A) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $95,972 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold A stock?
As of June 30, 2026, the largest Agilent Technologies (A) holders among the 13F filers tracked by SignalX were BlackRock ($3.4 billion), Vanguard Capital Management LLC ($2.5 billion), Vanguard Portfolio Management LLC ($1.9 billion), State Street Corp ($1.7 billion), BNY Mellon ($695.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was A's revenue in fiscal year 2025?
For the fiscal year ended October 31, 2025 (FY2025), Agilent Technologies (A) reported revenue of $6.9 billion (up 6.7% from FY2024) and net income of $1.3 billion. Diluted EPS was $4.57. The figures come from the XBRL data in the 10-K.
What are the main risks in A's latest 10-K?
In the 10-K filed December 22, 2025, Agilent Technologies (A) flagged: Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025. Geopolitical risk from U.S. tariff changes in H2 2025 increasing cost of revenue; mitigation expected in fiscal 2026 through supply chain and pricing actions. (AI summary of the Risk Factors section.)
What did A report in its latest 8-K?
Agilent Technologies (A) filed an 8-K on September 8, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Chairperson Boon Hwee Koh retiring September 4, 2026 after 23 years, with no operational or policy disagreements.
What are the latest A SEC filings?
Agilent Technologies (A) filed its latest 10-K annual report on December 22, 2025, a 10-Q quarterly report on September 1, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on September 10, 2026.
What is A's SEC CIK number?
Agilent Technologies (A)'s SEC Central Index Key (CIK) is 1090872. EDGAR lists every A filing under that number.
Ask anything about A
The research agent reads A's filings, financials, insider trades and 13F holders, then answers with sources.